Preparation and Evaluation of a Time-Controlled Release Capsule Made of Ethylcellulose for Colon Delivery of Drugs

References

• The beagle as an experimental dog, A. C. Anderson, L. S. Good. The Iowa University Press, Iowa City (1970); 226–231
   Google Scholar
• Ashford M., Fell J. T. Colonic delivery of drugs., in “Current status on targeted drug delivery to the gastrointestinal tract”. Capsugel Library (1993); 133–142
   Google Scholar
• Ashford M., Fell J. T., Attwood D., Woodhead P. J. An in vitro investigation into the suitability of pH dependent polymers for colonic targeting. Int. J. Pharm. (1993); 91: 241–245
   Web of Science ®Google Scholar
• Chen T. Formulation concerns on protein drugs. Drug Devel. Ind. Pharm. (1992); 18: 1311–1354
   Web of Science ®Google Scholar
• Cho M. J., Scieszka J. F., Burton P. S. Citric acid as an adjuvant for transepithelial transport. Int. J. Pharm. (1989); 52: 79–81
   Google Scholar
• Cohen A. M., Zsebo K. M., Inoue H., Hines D., Boone T. C., Chazin V. R., Tsai L., Ritch T., Souza L. M. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. (1987); 84: 2284–2288
   Google Scholar
• Eguchi K., Sasaki S., Tamura T., Sasaki Y., Shinkai T., Yamada K., Soejima Y., Fukuda M., Fujihara Y., Kunitou H., Tobinai K., Ohtsu T., Suemasu K., Takaku F., Saijo N. Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res. (1989); 49: 5221–5224
   PubMed Web of Science ®Google Scholar
• Friend D. R. Colon Specific drug delivery. Adv. Drug Deliv. Rev. (1991); 7: 149–199
   Web of Science ®Google Scholar
• “Oral colon-specific drug delivery”, D. R. Friend. CRC Press. 1992
   Google Scholar
• Gilligan C. A., Wan Po A. L. Oral vaccines: design and delivery. Int. J. Pharm. (1991); 75: 1–24
   Web of Science ®Google Scholar
• Hardy J. G. Colonic transit and drug delivery. Drug delivery to the gastrointestinal tract, J. G. Hardy, S. S. Davis, C. G. Wilson. John Wiley and Sons, Chichester (1989); 75–81
   Google Scholar
• Kjaergaard J.-J., Dideriksen K., Mourits-Andersen T. Some aspects of the pharmacokinetics of fluorescein in normal and in diabetic subjects. Int. J. Microcirc. Clin. Exptl. (1983); 2: 191–197
   PubMedGoogle Scholar
• Kopecek J. Reactive copolymers of N-(2-hydroxypropyl)-methaacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine I. Preparation, characterization and reaction with diamines. Makromol. Chem. (1977); 178: 2169–2173
   Web of Science ®Google Scholar
• Kraeling M. E.K., Ritschel W. A. Development of a colonic release capsule dosage form and the absorption of insulin. Meth. Find. Exp. Clin. Pharmacol. (1992); 14: 199–209
   PubMed Web of Science ®Google Scholar
• Layton J. E., Hockman H., Sheridan W. P., Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood (1989); 74: 1303–1307
   PubMed Web of Science ®Google Scholar
• Lee V. H.L., Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Advancd. Drug Del. Rev. (1990); 4: 171–207
   Google Scholar
• Lee V. H.L., Yamamoto A., Kompella U. B. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit., Rev. Ther. Drug Can. Sys. (1991); 8: 91–192
   PubMed Web of Science ®Google Scholar
• Mizuta H., Kawazoe Y., Haga K., Ogawa K., Yokobe T. Determination of small intestinal transit time in beagle dogs using salicylazosulfapylidine. Yakugaku Zasshi (1989); 109: 760–765
   PubMed Web of Science ®Google Scholar
• Morishita I., Morishita M., Takayama K., Machida Y, Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharmaceut. (1992); 78: 9–16
   Web of Science ®Google Scholar
• Nagata S., Tsuchiya M., Asano S., Kaziro Y., Yamazaki T., Yamamoto O., Hirata Y., Kubota N., Oheda N., Nomura H., Ono M. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature (1986); 319: 415–418
   PubMed Web of Science ®Google Scholar
• Nellans H. N. Mechanism of peptide and protein absorption (1) Paracellular intestinal transport: modulation of absorption. Adv. Drug Deliv. Rev. (1991); 7: 339–364
   Web of Science ®Google Scholar
• Nicola N. A. Granulocyte colony-stimulating factor and differentiation-induction in myeloid leukemic cells. Int. J. Cell Cloning (1987); 5: 1–15
   PubMedGoogle Scholar
• O'Hagan D. T. Oral delivery of vaccines: Function and clinical pharmacokinetic considerations. Clin. Pharmacokin. (1992); 22: 1–10
   PubMed Web of Science ®Google Scholar
• Pitt C. G. The controlled parenteral delivery of polypeptides and proteins. Int. J. Pharmaceut. (1990); 59: 173–196
   Web of Science ®Google Scholar
• Pusztai A. Transport of proteins through the membranes of the adult gastro-intestinal tract—a potential for drug delivery?. Advcd. Drug. Del. Rev. (1989); 3: 215–228
   Google Scholar
• Ritschel W. A. Targeting in the gastrointestinal tract: New approaches. Meth. Find. Exptl. Clin. Pharmacol. (1991); 13: 313–336
   PubMed Web of Science ®Google Scholar
• Saffran M., Kumar G. S., Savariar C., Burnham J. C., Williams F., Neckers D. C. A new approach to the oral administration of insulin and other peptide drugs. Science (1980); 233: 1081–1084
   Web of Science ®Google Scholar
• Smith P L, Wall D. A., Gochoco C. H., Wilson G. Oral absorption of peptides and proteins. Advancd. Drug Del. Rev. (1992); 8: 253–290
   Web of Science ®Google Scholar
• Swenson E. S., Curatolo W. J. Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Advancd. Drug Del. Rev. (1992); 8: 39–92
   Web of Science ®Google Scholar
• Szkrybalo W. Emarging trends in biotechnology: A perspective from the pharmaceutical industry. Pharmaceut. Res. (1987); 4: 361–363
   PubMed Web of Science ®Google Scholar
• Takada K., Tohyama Y., Oh-Hashi M., Yoshikawa H., Muranishi S., Shimosaka A., Kaneko T. Is recombinant human granulocyte colony-stimulating factor (G-CSF) orally available in rats?. Chem. Pharm. Bull. (1989); 37: 838–839
   PubMed Web of Science ®Google Scholar
• Takada K., Ushirogawa Y. Effect of pH, dietary proteins and trypsin inhibitors on the hydrolytic rate of human granulocyte colony-stimulating factor (G-CSF) by rat digestive enzymes. J. Pharmacobio-dyn. (1991); 14: 363–370
   PubMedGoogle Scholar
• Takada K., Nakahigashi Y., Tanaka T., Kishimoto S., Ushirogawa Y, Takaya T. Pharmacological activity of tablets containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharmaceut. (1994); 101: 89–96
   Web of Science ®Google Scholar
• Ushirogawa Y., Nakahigashi Y., Kiriyama A., Takada K. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharmaceut. (1992); 81: 133–141
   Web of Science ®Google Scholar
• Teshima H., Ishikawa J., Kitayama H., Yamagami T., Hiraoka A., Nakamura H., Shibata H., Masaoka T., Takaku F. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study. Exptl. Hematol. (1989); 17: 853–858
   PubMed Web of Science ®Google Scholar